文献速递妇科

症状性子宫肌瘤重复干预的临床与分子危险因素

Clinical and molecular risk factors for repeat interventions due to symptomatic uterine leiomyomas.
PubMed 文献 · Am J Obstet Gynecol · 2024-07-31

该回顾性队列纳入2009至2014年行腹腔镜或开腹子宫肌瘤剔除术的234例女性,中位随访11.4年,重复干预率为20%(46/234)。剔除肌瘤数目是危险因素(HR 1.21),手术时年龄(HR 0.94)和术后产次(HR 0.23)为保护因素。分子分析显示3/33(9%)患者重复手术肿瘤存在克隆相关性,3/33(9%)检出延胡索酸水合酶缺陷且均携带胚系突变。

要点

  • 子宫肌瘤剔除术后11.4年重复干预率为20%(46/234)。
  • 剔除肌瘤数目是重复干预危险因素(HR 1.21,95%CI 1.09-1.34)。
  • 手术时年龄(HR 0.94)和术后产次(HR 0.23)为保护因素。

核心结论

  • 子宫肌瘤剔除术后重复干预常见。
  • 子宫肌瘤通常独立发生,但部分共享克隆起源。
  • 重复肌瘤发生可能与遗传易感性相关,如胚系延胡索酸水合酶突变。
  • 同一患者多个肌瘤中检出不同的YEATS domain-containing protein 4体细胞突变,提示该基因可能在重复肌瘤中起作用。

研究设计与样本

  • 回顾性队列研究,纳入2009至2014年行腹腔镜或开腹子宫肌瘤剔除术的234例女性,中位随访11.4年(范围7.9-13.8年)。
  • 采用Kaplan-Meier估计和Cox比例风险模型分析临床危险因素对重复干预风险的影响。
  • 分子分析检测33例重复手术患者的133份福尔马林固定石蜡包埋肌瘤样本的3种主要驱动改变:mediator complex subunit 12突变、high mobility group AT-hook 2过表达和延胡索酸水合酶缺陷,使用Sanger测序和免疫组化。
  • 对21例在多次手术肿瘤中显示相同驱动改变的患者共52个肌瘤行全外显子测序以评估克隆关系。

主要发现

  • 子宫肌瘤剔除术后11.4年重复干预率为20%(46/234)。
  • 剔除肌瘤数目是重复干预的危险因素(HR 1.21;95%CI 1.09-1.34)。
  • 手术时年龄是保护因素(HR 0.94;95%CI 0.89-0.99)。
  • 术后产次是保护因素(HR 0.23;95%CI 0.09-0.60)。
  • 初次和非初次手术肿瘤的分子特征证实3/33(9%)患者肿瘤存在克隆关系;携带mediator complex subunit 12突变的肌瘤均未证实克隆相关;3/33(9%)患者重复肌瘤检出延胡索酸水合酶缺陷且均携带胚系延胡索酸水合酶突变;3/33(9%)患者各有2个肿瘤显示YEATS domain-containing protein 4体细胞突变且突变均不同、肿瘤非克隆相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Repeat leiomyoma occurrence or even reintervention is common after myomectomy. Little is known about the factors related to repeat interventions. OBJECTIVE: This study aimed to determine the frequency of leiomyoma-related reintervention after an initial laparoscopic or abdominal myomectomy and to analyze both clinical and molecular risk factors for reinterventions. Another objective was to define the frequency of clonally related tumors from repeat operations. STUDY DESIGN: This retrospective cohort study included 234 women who had undergone laparoscopic or abdominal myomectomy in 2009 to 2014. Information on repeat leiomyoma-related interventions as well as on other clinical factors was collected from medical records after a median follow-up time of 11.4 years (range 7.9-13.8 years) after the index procedure. The effect of clinical risk factors on the risk of reintervention was analyzed by the Kaplan-Meier estimator and the Cox proportional hazards model. For molecular analyses, we examined the mutation profiles of 133 formalin-fixed paraffin-embedded leiomyoma samples from 33 patients with repeat operations. We screened the tumors for the 3 primary leiomyoma driver alterations-mediator complex subunit 12 mutations, high mobility group AT-hook 2 overexpression, and fumarate hydratase-deficiency-utilizing Sanger sequencing and immunohistochemistry. To further assess the clonal relationship of the tumors, we executed whole-exome sequencing for 52 leiomyomas from 21 patients who exhibited the same driver alteration in tumors obtained from multiple procedures. RESULTS: Reintervention rate at 11.4 years after myomectomy was 20% (46/234). Number of leiomyomas removed at the index myomectomy was a risk factor (hazard ratio 1.21; 95% confidence interval 1.09-1.34). Age at index myomectomy (hazard ratio 0.94; 95% confidence interval 0.89-0.99) and postoperative parity (hazard ratio 0.23; 95% confidence interval 0.09-0.60) were protective factors. Molecular characterization of tumors from index and nonindex operations confirmed a clonal relationship of the tumors in 3/33 (9%) patients. None of the leiomyomas harboring a mediator complex subunit 12 mutation-the most common leiomyoma driver-were confirmed clonally related. Fumarate hydratase-deficiency was detected in repeat leiomyomas from 3/33 (9%) patients. All these patients harbored a germline fumarate hydratase mutation, which is distinctive for the hereditary leiomyomatosis and renal cell cancer syndrome. Finally, we identified 3 (3/33; 9%) patients with 2 tumors each displaying somatic mutations in a recently identified novel leiomyoma driver gene, YEATS domain-containing protein 4. All YEATS domain-containing protein 4 mutations were different and thus the tumors were not clonally related. CONCLUSION: Our study shows that reintervention is common after surgical myomectomy. Uterine leiomyomas typically develop independently, but some share a clonal origin. Repeat leiomyoma occurrence may be due to genetic predisposition, such as a germline fumarate hydratase mutation. Distinct somatic YEATS domain-containing protein 4 mutations identified in multiple leiomyomas from the same patient indicate a possible role for YEATS domain-containing protein 4 in repeat leiomyomas.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Khamaiseh S, Äyräväinen A, Arffman M, et al. Clinical and molecular risk factors for repeat interventions due to symptomatic uterine leiomyomas. Am J Obstet Gynecol. 2024. PMID: 39094728. doi:10.1016/j.ajog.2024.06.051

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。